Advertisement

Neoadjuvant Chemotherapy with FLEP Regimen for Incurable Gastric Cancer

  • Toshifusa Nakajima
  • Keiichiro Ohta
  • Shou Ishihara
  • Shigekazu Ohyama
  • Mitsumasa Nishi
  • Yasuhiko Ohashi
  • Akio Yanagisawa
  • Yo Kato

Abstract

Although the results of treatment for gastric cancer in Japan have improved, the prognosis of advanced stage disease remains poor [1,2]. Neither chemotherapy nor surgery alone has produced long-term survivors among patients with advanced disease. Our database of gastric cancer cases (11489 cases treated in our hospital from 1946 to 1994) shows that median survival time was 6 months for patients with noncurative surgery and 4 months for nonsurgically treated cases [3]. Our conventional strategy for advanced gastric cancer (including extended radical surgery followed by postoperative chemotherapy) yielded a plateau in the survival benefit. However, recent chemotherapy regimens with high response rates [4, 5, 6, 7, 8, 9] seem to allow radical surgery for initially unresectable disease. Since 1989 at the Cancer Institute Hospital, Tokyo, we have attempted to treat advanced unresectable gastric cancer patients with a four-drug combination chemotherapy with systemic and regional delivery followed by radical gastrectomy. The treatment results have been reported elsewhere [10].

Keywords

Gastric Cancer Clin Oncol Advanced Gastric Cancer Peritoneal Dissemination Celiac Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nakajima T, Nishi M, Kajitani T (1991) Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9700 cases in the Cancer Institute Hospital, Tokyo. Semin Surg Oncol 7:365–372PubMedCrossRefGoogle Scholar
  2. 2.
    Nakajima T, Ota K, Ishihara S, Yamada H, Nishi M (1993) Extended radical surgery for advanced gastric cancer. Surg Oncol Clin North Am 2:467–481Google Scholar
  3. 3.
    Nakajima T (1994) Tabular analysis of 10000 cases of gastric cancer (in Japanese). Jpn J Cancer Chemother 21:1813–1897Google Scholar
  4. 4.
    Klein HO, Wickrammanayake PD, Farrokh GR (1986) 5-Fluorouracil, adriamycin and methotrexate-a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Am Soc Clin Oncol 5:84Google Scholar
  5. 5.
    Moertel CG, Ribin J, O’Connell MJ, Schutt AJ (1986) A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 4:1053–1057PubMedGoogle Scholar
  6. 6.
    Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G, Sydney Cooperative Oncology Group (1986) Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 4:1348–1355PubMedGoogle Scholar
  7. 7.
    Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Beunte H (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317PubMedGoogle Scholar
  8. 8.
    Wilke H, Preusser P, Fink U, Achterrath W, Meyer H-J, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Köhne-Wömpner CH, Könne-Wömpner CH, Harstrick AC, Schmoll HJ (1990) New developments in the treatment of gastric carcinoma. Semin Oncol 17:61–70PubMedGoogle Scholar
  9. 9.
    Bruckner HW, Chesser MR, Wong H, Mandeli J (1991) Folate biochemical modulation regimen for the treatment of gastric cancer. J Clin Gastroenterol 13:384–389PubMedCrossRefGoogle Scholar
  10. 10.
    Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A (1997) Combined inductive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203–208PubMedCrossRefGoogle Scholar
  11. 11.
    Collins JM (1984) Pharmacological rationale for regional drug delivery. J Clin Oncol 2:498–504PubMedGoogle Scholar
  12. 12.
    Buchwald H, Grage TB, Vassilopoulos PR Rhode TD, Varco RL, Blackshear PJ (1980) Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 45:866–869PubMedCrossRefGoogle Scholar
  13. 13.
    Lee Y-TM (1987) Regional infusion for metastatic liver tumors. In: Lokich JJ (ed) Cancer chemotherapy by infusion. Precept Press, Chicago, pp 415–434CrossRefGoogle Scholar
  14. 14.
    Stephens FO, Adams BG, Crea P (1986) Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 162: 370–374PubMedGoogle Scholar
  15. 15.
    Aigner KR, Benthin F, Müller H (1991) Celiac axis infusion (CAI) chemotherapy for advanced gastric cancer. In: Sugarbaker PH (ed) Management of gastric cancer. Kluwer, Boston, pp 357–362CrossRefGoogle Scholar
  16. 16.
    Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D (1991) Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 68:1501–1506PubMedCrossRefGoogle Scholar
  17. 17.
    Kerr DJ (1989) 5-Fluorouracil and folinic acid: interesting biochemistry of effective treatment? Br J Cancer 60:807–808PubMedCrossRefGoogle Scholar
  18. 18.
    O’Connell MJ (1989) A phase III trial of 5-fluorouracil and leucovorin in the treatment of colorectal cancer. Cancer 63:1026–1030CrossRefGoogle Scholar
  19. 19.
    Petrelli N, Douglass HO Jr, Herrera L, Russel D, Stablein D, Bruckner H, Mayer R, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gayner E, Louth A, Kaiser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419–1426PubMedGoogle Scholar
  20. 20.
    Kremer B, Henne-Bruns D, Weh HJ, Effenberger T (1989) Advanced gastric cancer: a new combined surgical and oncological approach. J Hepatogastroenterol 36:23–26Google Scholar
  21. 21.
    Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, Yaosaka T, Takahashi H, Ito T, Sasai T, Akiya T, Akazawa S, Betsuyaku T, Taguchi S (1991) A cooperative randomized study on tegafur plus mitomycin C, versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 82:613–620PubMedCrossRefGoogle Scholar
  22. 22.
    Wils JA, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N (1991) Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9:827–831PubMedGoogle Scholar
  23. 23.
    Anderson H, Scarffe JH, Ranson M, Kamthan AG, Dougal M, Russell SA, Wilkinson MJS, Ostick DG (1991) MMAF for advanced gastric cancer. Eur J Cancer 27:1234–1238PubMedCrossRefGoogle Scholar
  24. 24.
    Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, Yoshino M, Yoshimori M (1991) An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 21:120–124PubMedGoogle Scholar
  25. 25.
    Taguchi T (1989) Combination chemotherapy with etoposide, adriamycin (A), and cisplatin (P) (EAP) for advanced gastric cancer. Proc Am Soc Clin Oncol 8:108–108Google Scholar
  26. 26.
    Rath U, Flechtner H, Selbach J, Harjung H, Manegold C, Kabelitz K, Trux FA, Edler L, Schlag P, Queisser W (1990) Etoposide, adriamycin, and cisplatinum (EAP) combination chemotherapy for advanced gastric cancer: a phase II trial by the “Chemotherapiegruppe Gastrointestinaler Tumoren (CGT).” Onkologie 13:194–197PubMedCrossRefGoogle Scholar
  27. 27.
    Lerner A, Gonin B, Steele GDJ, Mayer RJ (1992) Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10:536–540PubMedGoogle Scholar
  28. 28.
    Kelsen D, Atig OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10:541–548PubMedGoogle Scholar
  29. 29.
    Hansen RM (1991) 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest 9:637–642PubMedCrossRefGoogle Scholar
  30. 30.
    Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664PubMedGoogle Scholar
  31. 31.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, Bruijn EA, Graves T, Mullins RE, Schlag P (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16:83–97PubMedGoogle Scholar
  32. 32.
    Leichman L, Silberman H, Leichman C, Spears C, Ray M, Muggia F, Kiyabu M, Radin R, Laine L, Stain S, Fuerst S, Groshen S, Donovan A (1992) Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 10:1933–1942PubMedGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Toshifusa Nakajima
    • 1
  • Keiichiro Ohta
    • 1
  • Shou Ishihara
    • 1
  • Shigekazu Ohyama
    • 1
  • Mitsumasa Nishi
    • 1
  • Yasuhiko Ohashi
    • 2
  • Akio Yanagisawa
    • 3
  • Yo Kato
    • 3
  1. 1.Division of Gastrointestinal SurgeryCancer Institute HospitalTokyoJapan
  2. 2.Division of Medical OncologyCancer Institute HospitalTokyoJapan
  3. 3.Division of PathologyCancer InstituteTokyoJapan

Personalised recommendations